D J Kereiakes
Overview
Explore the profile of D J Kereiakes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kereiakes D, Young J, Runyon J, Shimshak T
J Invasive Cardiol
. 2001 Jun;
13(6):437-8.
PMID: 11385164
No abstract available.
12.
Steinhubl S, Talley J, Braden G, Tcheng J, Casterella P, Moliterno D, et al.
Circulation
. 2001 May;
103(21):2572-8.
PMID: 11382726
Background: The optimal level of platelet inhibition with a glycoprotein (GP) IIb/IIIa antagonist necessary to minimize thrombotic complications in patients undergoing a percutaneous coronary intervention (PCI) is currently unknown. Methods...
13.
Kereiakes D, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, et al.
J Invasive Cardiol
. 2001 Apr;
13(4):272-8.
PMID: 11287711
Randomized controlled trials of patients with non-ST segment elevation acute coronary syndromes have established the superiority of enoxaparin (versus unfractionated heparin) for reducing adverse ischemic outcomes. Furthermore, adjunctive abciximab therapy...
14.
Reddy M, Carmody T, Kereiakes D
Catheter Cardiovasc Interv
. 2001 Apr;
52(4):486-8.
PMID: 11285605
Acute thrombocytopenia associated with abciximab therapy has been well described, although the exact mechanism remains obscure. We report a case of delayed severe thrombocytopenia associated with abciximab therapy for percutaneous...
15.
Dippel E, Kereiakes D, Tramuta D, Broderick T, Shimshak T, ROTH E, et al.
Catheter Cardiovasc Interv
. 2001 Mar;
52(3):279-86.
PMID: 11246236
Coronary perforation is an uncommon but potentially life-threatening complication of percutaneous coronary intervention. The use of both atheroablative technologies for coronary intervention and adjunctive platelet glycoprotein blockade pharmacology may increase...
16.
Kereiakes D, Kleiman N, Fry E, Mwawasi G, Lengerich R, Maresh K, et al.
Am Heart J
. 2001 Mar;
141(3):348-52.
PMID: 11231430
Background: Despite proved efficacy for either dalteparin or platelet glycoprotein IIb/IIIa blockade in improving clinical outcomes of patients with non-ST-segment elevation acute coronary syndromes, algorithms guiding concomitant therapy with these...
17.
Kereiakes D, Young J, Broderick T, Shimshak T, Abbottsmith C
Am J Cardiol
. 2001 Feb;
86(12B):10M-17M.
PMID: 11206013
Early coronary intervention in patients with non-ST-segment elevation myocardial infarction (MI) and unstable angina may be made safer and more efficacious with concomitant therapies, including glycoprotein IIb/IIIa inhibitors and low-molecular-weight...
18.
Young J, Kereiakes D, Grines C
J Invasive Cardiol
. 2001 Jan;
12 Suppl E:E14-8;discussion E25-8.
PMID: 11156724
Early coronary intervention in patients with non-ST segment elevation acute coronary syndromes (ACS) may be facilitated by adjunctive pharmacotherapies. Concomitant therapies such as low-molecular-weight heparins and platelet glycoprotein (GP) IIb/IIIa...
19.
Antman E, Kereiakes D
J Invasive Cardiol
. 2001 Jan;
12 Suppl E:E1-4;discussion E25-8.
PMID: 11156721
Acute coronary syndromes (ACS) represent a spectrum of diseases resulting from a disturbance in myocardial blood flow. The etiology of this disturbance stems from either partial or complete thrombotic occlusion...
20.
Baim D, Cutlip D, OShaughnessy C, Hermiller J, Kereiakes D, Giambartolomei A, et al.
Am J Cardiol
. 2001 Jan;
87(2):152-6.
PMID: 11152830
The NIR stent is a novel second generation tubular stent that was designed to overcome some of the limitations of the earlier Palmaz-Schatz (PS) stent design. The NIR Vascular Advanced...